Literature DB >> 25111897

HDAC6 sustains growth stimulation by prolonging the activation of EGF receptor through the inhibition of rabaptin-5-mediated early endosome fusion in gastric cancer.

Se Jin Park1, Jeong Kyu Kim1, Hyun Jin Bae1, Jung Woo Eun1, Qingyu Shen1, Hyung Seok Kim1, Woo Chan Shin1, Hee Doo Yang1, Eun Kyung Lee2, Jueng Soo You3, Won Sang Park1, Jung Young Lee1, Suk Woo Nam4.   

Abstract

The aberrant regulation of histone deacetylase 6 (HDAC6) contributes to malignant progression in various types of cancer, but the mechanism underlying gastric carcinogenesis remains unknown. Aberrant HDAC6 overexpression was observed in a subset of human gastric cancer cells. HDAC6 knockdown caused the significant inhibition of gastric cancer cell growth without affecting the transition of cell cycles or the processing of cell death. We demonstrate that an increase in epidermal growth factor receptor (EGFR) signaling through decreased EGFR degradation was mediated by HDAC6 in gastric carcinogenesis. These results establish a molecular mechanism responsible for oncogenic HDAC6, explaining how EGFR signaling induced by the growth factor is sustained during the malignant progression of gastric cancer.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  EGF receptor; Endocytosis; Histone deacetylase 6; Rabaptin-5

Mesh:

Substances:

Year:  2014        PMID: 25111897     DOI: 10.1016/j.canlet.2014.07.041

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  10 in total

1.  Deacetylation of tumor-suppressor MST1 in Hippo pathway induces its degradation through HBXIP-elevated HDAC6 in promotion of breast cancer growth.

Authors:  L Li; R Fang; B Liu; H Shi; Y Wang; W Zhang; X Zhang; L Ye
Journal:  Oncogene       Date:  2015-12-14       Impact factor: 9.867

2.  HDAC6/FOXP3/HNF4α axis promotes bile acids induced gastric intestinal metaplasia.

Authors:  Luyao Zhang; Na Wang; Min Chen; Siran Wu; Jiaoxia Zeng; Fenli Zhou; Qiong Wu; Junye Liu; Yongquan Shi
Journal:  Am J Cancer Res       Date:  2022-03-15       Impact factor: 6.166

Review 3.  The dual functions of Rab11 and Rab35 GTPases-regulation of cell division and promotion of tumorigenicity.

Authors:  Paulius Gibieža; Vilma Petrikaitė
Journal:  Am J Cancer Res       Date:  2021-05-15       Impact factor: 6.166

4.  MicroRNA-22 represses glioma development via activation of macrophage-mediated innate and adaptive immune responses.

Authors:  Jiajie Tu; Yilong Fang; Dafei Han; Xuewen Tan; Zhen Xu; Haifeng Jiang; Xinming Wang; Wenming Hong; Wei Wei
Journal:  Oncogene       Date:  2022-03-12       Impact factor: 9.867

Review 5.  Rab-mediated vesicle trafficking in cancer.

Authors:  Hong-Tai Tzeng; Yi-Ching Wang
Journal:  J Biomed Sci       Date:  2016-10-06       Impact factor: 8.410

6.  Rabaptin5 targets autophagy to damaged endosomes and Salmonella vacuoles via FIP200 and ATG16L1.

Authors:  Valentina Millarte; Simon Schlienger; Simone Kälin; Martin Spiess
Journal:  EMBO Rep       Date:  2021-10-26       Impact factor: 8.807

Review 7.  Role of HDAC6 and Its Selective Inhibitors in Gastrointestinal Cancer.

Authors:  Bingyi Zhou; Deliang Liu; Yuyong Tan
Journal:  Front Cell Dev Biol       Date:  2021-12-02

8.  Establishment of DNA Methylation Profile Associated with TCM Syndrome in Endometriosis.

Authors:  Xinyue Wang; Zhaofeng Zhang; Weiwei Zeng; Yuqing Zhong; Dandan Xie; Weiqiang Zhu; Fujia Chen; Jing Du; Tingting Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2022-04-11       Impact factor: 2.650

Review 9.  Targeting HDAC6 to Overcome Autophagy-Promoted Anti-Cancer Drug Resistance.

Authors:  Hyein Jo; Kyeonghee Shim; Dooil Jeoung
Journal:  Int J Mol Sci       Date:  2022-08-24       Impact factor: 6.208

10.  Expression and prognostic analyses of HDACs in human gastric cancer based on bioinformatic analysis.

Authors:  Luting Chen; Yuchang Fei; Yurong Zhao; Quan Chen; Peifeng Chen; Lei Pan
Journal:  Medicine (Baltimore)       Date:  2021-07-09       Impact factor: 1.817

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.